Sandra Larkin, MS

In her role as laboratory supervisor, Sandy ensures compliance of the lab with UCSF policies and procedures, prepares study budgets and agreements, and manages the recharge lab billing for our clients.  Sandy performs calibration, maintenance, and quality control for instrumentation of the RBC lab, and is involved in the design and development of experiments protocols. She interacts with our clients, acquires and analyzes data, maintains databases, and submits written reports to our clients.

Publications

  1. Styles L, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers FA. Decrease of VLA-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood. 1997. 89(7) 2554-9.
  2. deJong K, Larkin S, Eber S, Franck PFH, Roelofsen B, Kuypers FA. Hereditary spherocytosis and eliptocytosis erythrocytes show a normal transbilayer phospholipid distribution. Blood. 1999. 94:1. 319-25.
  3. Morris CR, Kuypers FA, Larkin S, Sweeters N, Simon J, Vichinsky EP, Styles LA. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. J Ped Hem/Onc. 2000. 111(2):498-500.
  4. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Ped Hem/Onc. 2000. 22(6): 515-20.
  5. deJong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 2001. 98(3): 860-67.
  6. Neidlinger NA, Hirvela ER, Skinner RA, Larkin SK, Harken AH, Kuypers FA. Postinjury serum secretory phospholipase A2 correlates with hypoxemia and clinical status at 72 hours. J Am Coll Surg. 2005. 200(2):173-8.
  7. Bargoma EM, Mitsuyoshi JK, Larkin SK, Styles LA, Kuypers FA, Test ST. Serum C-reactive protein parallels secretory phospholipase A2 in Sickle Cell Disease Patients with vasoocclusive crisis or acute chest syndrome. Blood. 2005. 105(8) 3384-5.
  8. Morris CR, Kuypers FA, Kato MD, Lavrisha L, Larkin S, Singer T, Vichinsky EP. Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 2005. 481-5
  9. Neidlinger NA, Larkin SK, Bhagat A, Victorino GP, Kuypers FA. Hydrolysis of phosphatidylserine-exposiing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem. 2006. 282(2):775-81.
  10. Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol. 2007. 136(2):343-4.
  11. Kuypers FA, Larkin SK, Emeis J, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserinc on cell surfaces and consequesnt antithrombotic activity. Thromb Haemost. 2007. 97(3):478-86. 
  12. Singer ST, Vichinsky EP, Larkin S, Oliveri N, Sweeters N, Kuypers FA. Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells. Am J Hematol. 2008. 83(11):842-5.
  13. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008. 111(1): 402-410.
  14. Serikov V, Hounshell C, Larkin S, Green W, Ikeda H, Walters MC, Kuypers FA. Human term placenta as a source of hematopoietic cells. Exp Biol Med. 2009. 234(7): 813-23.
  15. Moyer JD, Nowak RB, Kim NE, Larkin SK, Peters LL, Hartwig J, Kuypers FA, Fowler VM. Tropomodulin 1-null mice have a mild spherocytic eliptocytosis with appearance of Tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood. 2010. 116(14):2590-9.
  16. Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A Pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011. 153(5): 655-63.
  17. Mansour KM, Kuypers FA, Wang TN, Miller AM, Larkin SK, Morris CR. Secretory phospholiapase A2: a marker of infection in febrile children presenting to a pediatric ED. Am J Emerg Med. 2011. 29(9):1163-8.
  18. Smith S, Witkowski A, Moghul A, Yoshinaga Y, Nefedov M, deJong P, Feng D, Fong L, Tu Y, Hu Y, Young SG, Pham T, Cheung C, Katzman SM, Brand MD, Quintan CL, Fens M, Kuypers F, Misquitta S, Griffey SM, Tran S, Gharib A, Knudsen J, Hannibal-Bach HK, Wang G, Larkin S, Thweatt J, Pasta S. Compromised mitochondrial fatty acid synthesis in transgenic mice results in defective protein lipoylation and energy disequilibrium. PLoS One. 2012. 7(10):e47196.
  19. Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Oliveri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Sug J, Kuypers FA, Vichinsky EP. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica. 2013. 98(9): 1359-67.
  20. Stookey JD, Klein A, Hamer J, Chi C, Higa A, Ng V, Arieff A, Kuypers FA, Larkin S, Perrier E, Lang F. RBC deformability and amino acid concentrations after hypo-osmotic challenge may reflect chronic cell hydration status in healthy young men. Physiol Rep. 2013. 
  21. Fens MH, Larkin SK, Oronsky B, Scicinski J, Morris CR, Kuypers FA. The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions. PLoS One. 2014. 9(7)
  22. Singer ST, Kuypers F, Fineman J, Gildengorin G, Larkin S, Sweeters N, Rosenfeld H, Kurio G, Higa A, Jeng M, Huang J, Vichinsky EP. Elevated tricuspid regurgitant jet velocity in subgroups of thalassemia patients: insight into pathophysiology and the effect of splenectomy. Ann Hematol. 2014. 93(7):1139-48.
  23. Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Oliveri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh J, Vichinsky EP, Kuypers FA.Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol. 2015. 169(6):887-98.
  24. Marsh A, Schiffelers R, Kuypers F, Larkin S, Gildengorin G, vanSolinge W, Hoppe C. Microparticles as biomarkers of osteonecrosis of the hip in sickle cell disease. Br J Haematol. 2015. 168(1):135-8.
  25. Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, and Oronsky B. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Med Oncol. 2016. 33(7):63
  26. Soupene E, Borja MS, Borda M, Larkin SK, Kuypers FA. Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood. Exp Biol Med. 2016. 241(17):1933-1942.
  27. Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, and Oronsky B. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Med Oncol. 2016. 33(8):85.
  28. Soupene E, Larkin SK, Kuypers FA. Featured Article: Depletion of HDL3 high density lipoprotein and altered functionality of HDL2 in blood from sickle cell patients. Exp Biol Med. 2017. 242(12): 1244-53.
  29. Hoppe C, Jacob E, Styles L, Kuypers F, Larkin S, Vichinsky E. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. Br J Haematol. 2017. 177(4):620-629.
  30. Michlitsch J, Larkin S, Vichinsky E, and Kuypers F, Vincristine-induced anemia in Hereditary Spherocytosis, Exp Biol Med. 2019. 244(10):850-4.
  31. Goktas P, Sukharevsky IO, Larkin S, Kuypers FA, Yalcin O, and Altintas A. Image-based flow cytometry and angle-resolved light scattering to define the sickling process. Cytometry. 2019. 95(5): 488-98.
  32. Morris CR, Kuypers FA, Hagar R, Larkin S, Lavrisha L, Saulys A, Vichinsky EP, and Suh JH. Implications for the metabolic fate of oral glutamine supplementation within plasma and erytrhrocytes of patients with sickle Cell Disease: A pharmacokinetics study. Compliment Ther Med. 2022. 64:1-6.
  33. Killilea DW, Kuypers FA, Larkin SK, and Schultz K. Blood draw site and analytic device influence hemoglobin measurements. PLoS One. 2022. 17(11):1-19.
  34. Vissa M, Larkin SK, Vichinsky EP, Kuypers FA, and Soupene E (2023). Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease. Exp Biol Med. 2023.
  35. Phan V, Hershenson J, Caldarera L, Larkin SK, Wheeler K, Cortez AL, Dulman R, Briere N, Lewis A, Kuypers FA, Yang E. Effect of Volelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot study. Ped Blood Cancer. 2023. 70(8)